Toll-like receptor 4 upregulation by angiotensin II contributes to hypertension and vascular dysfunction through reactive oxygen species production
EntityUAM. Departamento de Farmacología
PublisherPublic Library of Science
10.1371/journal.pone.0104020Plos One 9.8 (2014): e104020
Funded byThis work was supported by MINECO (SAF2012-36400), ISCIII (RD12/0042/0024), MEC (PHB2011-0001-PC), URJC (PRIN13_CS12), CAPES and PRONEXFAPES/ CNPq. PRB was a fellow of CAPES
Subjectsblood pressure; cardiovascular function; hypertension; oxidative stress; vascular disease; toll like receptor 4; Medicina
Rights© 2014 De Batista et al.
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.
Hypertension is considered as a low-grade inflammatory disease, with adaptive immunity being an important mediator of this pathology. TLR4 may have a role in the development of several cardiovascular diseases; however, little is known about its participation in hypertension. We aimed to investigate whether TLR4 activation due to increased activity of the reninangiotensin system (RAS) contributes to hypertension and its associated endothelial dysfunction. For this, we used aortic segments from Wistar rats treated with a non-specific IgG (1 μg/day) and SHRs treated with losartan (15 mg/kġday), the non-specific IgG or the neutralizing antibody anti-TLR4 (1 μg/day), as well as cultured vascular smooth muscle cells (VSMC) from Wistar and SHRs. TLR4 mRNA levels were greater in the VSMC and aortas from SHRs compared with Wistar rats; losartan treatment reduced those levels in the SHRs. Treatment of the SHRs with the anti-TLR4 antibody: 1) reduced the increased blood pressure, heart rate and phenylephrine-induced contraction while it improved the impaired acetylcholine-induced relaxation; 2) increased the potentiation of phenylephrine contraction after endothelium removal; and 3) abolished the inhibitory effects of tiron, apocynin and catalase on the phenylephrine-induced response as well as its enhancing effect of acetylcholine-induced relaxation. In SHR VSMCs, angiotensin II increased TLR4 mRNA levels, and losartan reduced that increase. CLI-095, a TLR4 inhibitor, mitigated the increases in NAD(P)H oxidase activity, superoxide anion production, migration and proliferation that were induced by angiotensin II. In conclusion, TLR4 pathway activation due to increased RAS activity is involved in hypertension, and by inducing oxidative stress, this pathway contributes to the endothelial dysfunction associated with this pathology. These results suggest that TLR4 and innate immunity may play a role in hypertension and its associated end-organ damage
Google Scholar:De Batista, Priscila Rossi - Palacios, Roberto - Martín, Ángela L. - Hernanz, Raquel - Médici, Cindy T. - Silva, Marito A S C - Rossi, Emilly M. - Aguado, Andrea - Vassallo, Dalton Valentim - Salaíces, Mercedes - Alonso, María Jesús
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
MAPK pathway activation by chronic lead-exposure increases vascular reactivity through oxidative stress/cyclooxygenase-2-dependent pathways Simões, Maylla Ronacher; Aguado, Andrea; Fiorim, Jonaína; Silveira, Edna Aparecida; Azevedo, Bruna Fernandes; Toscano, Cindy Medice; Zhenyukh, Olha; Bríones, Ana María; Alonso, María Jesús; Vassallo, Dalton Valentim; Salaíces, Mercedes
Padilha, Alessandra Simão; Salaíces, Mercedes; Vassallo, Dalton Valentim; Batista, Priscila Rossi; Siman, Fabiana Dayse Magalhães